MCL1 and hematologic disorder: Two other MCL-1 inhibitors AZD-5991520 and AMG-176521 have also entered clinical trials to evaluate their safety, PKs, and antitumor response in patients with hematological malignancies (NCT03218683 and NCT02675452).